Document is current

Article History

Received: 18 November 2024

Revised: 19 December 2024

Accepted: 1 January 2025

First Online: 14 January 2025

Declarations

:

: This study protocol was reviewed and approved by the Independent Review Board/Ethics Committee of the Federation France Macula (approval number: 2024-17).

: Patients gave their informed consent to be treated with intravitreal injections. After the occurrence of intraocular inflammation, they were informed of our intent to report this complication, and they gave their consent for this reporting.

: S.Y.C. is a consultant for Abbvie, Bayer, Novartis, Roche, and Thea. S.N.-B. and F.F. are consultants for Abbvie, Bayer, and Novartis. S.M. is a consultant for Abbvie, Bayer, Novartis, and Roche. A.B., J.S., and M.P. have no conflicts of interest to disclose. Roche/Genentech, the manufacturer of faricimab, was not involved in the conduct or design of this study or in the decision to analyze and report the findings.